Emerging treatments
Cosibelimab
Cosibelimab, a human IgG1 monoclonal antibody which blocks PD-L1 binding to PD-1 and B7.1 receptors on T cells and antigen presenting cells, has been approved by the US Food and Drug Administration (FDA) for the treatment of adults with metastatic cutaneous SCC or locally advanced SCC who are not candidates for curative surgery or radiotherapy. The approval is based on the results of one open-label, multicentre, multiregional, multicohort, phase 1 trial which reported a 47% (95% CI 36% to 59%) objective response rate for patients treated with cosibelimab.[120] Common adverse effects reported in the trial include fatigue, rash, and anaemia; some patients experienced immune-related adverse effects.[120] The NCCN includes cosibelimab as an alternative treatment for patients with SCC in whom curative surgery or RT is not feasible.[74]
Use of this content is subject to our disclaimer